Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial

OBJECTIVE: To analyze the efficacy and safety of nintedanib in patients with fibrosing autoimmune disease–related interstitial lung diseases (ILDs) with a progressive phenotype. METHODS: The INBUILD trial enrolled patients with a fibrosing ILD other than idiopathic pulmonary fibrosis, with diffuse f...

Descripción completa

Detalles Bibliográficos
Autores principales: Matteson, Eric L., Kelly, Clive, Distler, Jörg H. W., Hoffmann‐Vold, Anna‐Maria, Seibold, James R., Mittoo, Shikha, Dellaripa, Paul F., Aringer, Martin, Pope, Janet, Distler, Oliver, James, Alexandra, Schlenker‐Herceg, Rozsa, Stowasser, Susanne, Quaresma, Manuel, Flaherty, Kevin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321107/
https://www.ncbi.nlm.nih.gov/pubmed/35199968
http://dx.doi.org/10.1002/art.42075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321107/
https://www.ncbi.nlm.nih.gov/pubmed/35199968
http://dx.doi.org/10.1002/art.42075

Ejemplares similares